亚太地区 T 细胞治疗市场预测至 2030 年 - 区域分析 - 按模式（研究和商业化）、治疗类型 [CAR T 细胞疗法和基于 T 细胞受体 (TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）
No. of Pages: 76 | Report Code: BMIRE00029304 | Category: Life Sciences
No. of Pages: 76 | Report Code: BMIRE00029304 | Category: Life Sciences
有针对性的治疗、更快、更有效的恢复以及减少副作用是T细胞疗法的优点。在全球范围内，由于获得了各种批准，细胞疗法被广泛采用。例如，2023年：杨森的CAR-T细胞疗法CARVYKTI (Ciltacabtagene Autoleucel)已被澳大利亚治疗产品管理局批准作为多发性骨髓瘤患者的四线治疗。
2023年：中国国家药品监督管理局已批准信达生物和IASO生物技术公司（IASO Bio）的Fucaso（equecabtagene autoleucel）用于治疗成人复发或难治性多发性骨髓瘤（RRMM）患者。 2023年6月，该机构批准了该疗法的新药申请（NDA）。
2023年：首个人源化CD19靶向嵌合抗原受体T细胞（CAR-T细胞）治疗产品NexCAR19（Actalycabtagene autoleucel） ），已获得印度中央药物标准控制组织（CDSO）批准用于治疗复发/难治性 B 细胞淋巴瘤和白血病。免疫过继细胞疗法在IIT孟买孵化。
2023年：复星凯特生物科技研发的自体CAR T细胞疗法益凯达（axicabtagene ciloleucel）获得中国国家药品监督管理局（NMPA）批准）用作大 B 细胞淋巴瘤患者的二线治疗。
2020 年：日本厚生劳动省 (MHLW) 授予生物医学研究与创新基金会神户公司 (“FBRI”) 获得为日本患者生产和分销 Kymriah (tisagenlecleucel) 的营销许可。诺华公司今天宣布了这一消息。凭借这一许可，FBRI 现在成为亚洲唯一授权的 CAR-T 细胞疗法商业生产工厂。
因此，T 细胞疗法批准数量的增加正在推动市场增长。
>
亚太 T 细胞治疗市场分为中国、日本、印度、韩国、澳大利亚等亚太地区。由于 CAR T 细胞疗法可有效治疗癌症，从而推动该地区的市场增长，预计亚太地区市场将出现显着增长。该地区正在进行许多 CAR T 细胞疗法的临床试验，这为亚太地区提供了新的机遇。中国是全球开展CAR T细胞临床试验最多的国家，医院开展的临床试验也最多。中国正在形成 CAR-T 产业链，包括正在进行和预期的监管改革，以有利于获得此类新疗法。中国于 2021 年 9 月批准了其首个 CAR T 细胞疗法 JW Therapeutics 的 relmacabtagene autoleucel，用于治疗经过两种或多种全身治疗后的复发或难治性大 B 细胞淋巴瘤 (r/r LBCL) 成人患者。 /p>
亚太 T 细胞治疗市场分为模式、治疗类型、适应症和国家。
根据模式，亚太 T 细胞治疗市场分为研究并商业化。商业化细分市场将在2022年占据更大的市场份额。
根据治疗类型，亚太T细胞治疗市场分为CAR T细胞疗法和T细胞受体（TCR）疗法。到2022年，CAR T细胞治疗领域将占据更大的市场份额。
根据适应症，亚太地区T细胞治疗市场分为血液恶性肿瘤和实体瘤。到 2022 年，血液恶性肿瘤领域占据最大的市场份额。
按国家/地区划分，亚太地区 T 细胞治疗市场分为中国、日本、澳大利亚、韩国和亚太地区其他地区。 2022年，中国在亚太T细胞治疗市场占据主导地位。
百时美施贵宝公司、吉利德科学公司、信达生物制药公司、杨森全球服务有限责任公司、JW（开曼）治疗有限公司、传奇生物科技公司、和诺华公司是亚太 T 细胞治疗市场上的一些领先公司。
Strategic insights for Asia Pacific T Cell Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 251.99 Million |
| Market Size by 2030 | US$ 882.72 Million |
| Global CAGR (2022 - 2030) | 17.0% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By 模式
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific T Cell Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
1. Bristol-Myers Squibb Co
2. Gilead Sciences Inc
3. Innovent Biologics Inc
4. Janssen Global Services LLC
5. JW (Cayman) Therapeutics Co Ltd
6. Legend Biotech Corp
7. Novartis AG
The Asia Pacific T Cell Therapy Market is valued at US$ 251.99 Million in 2022, it is projected to reach US$ 882.72 Million by 2030.
As per our report Asia Pacific T Cell Therapy Market, the market size is valued at US$ 251.99 Million in 2022, projecting it to reach US$ 882.72 Million by 2030. This translates to a CAGR of approximately 17.0% during the forecast period.
The Asia Pacific T Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific T Cell Therapy Market report:
The Asia Pacific T Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific T Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific T Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific T Cell Therapy Market
